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Abstract
Forkhead box M1 (FoxM1) oncogenic transcription factor represents an attractive therapeutic target in the fight against
cancer, because it is overexpressed in a majority of human tumors. Recently, using a cell-based assay system we identified
thiazole antibiotic Siomycin A as an inhibitor of FoxM1 transcriptional activity. Here, we report that structurally similar
thiazole antibiotic, thiostrepton also inhibits the transcriptional activity of FoxM1. Furthermore, we found that these
thiopeptides did not inhibit the transcriptional activity of other members of the Forkhead family or some non-related
transcription factors. Further experiments revealed that thiazole antibiotics also inhibit FoxM1 expression, but not the
expression of other members of the Forkhead box family. In addition, we found that the thiazole antibiotics efficiently
inhibited the growth and induced potent apoptosis in human cancer cell lines of different origin. Thiopeptide-induced
apoptosis correlated with the suppression of FoxM1 expression, while overexpression of FoxM1 partially protected cancer
cells from the thiazole antibiotic-mediated cell death. These data suggest that Siomycin A and thiostrepton may specifically
target FoxM1 to induce apoptosis in cancer cells and FoxM1 inhibitors/thiazole antibiotics could be potentially developed as
novel anticancer drugs against human neoplasia.
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Introduction
Forkhead box M1 (FoxM1) [1], a transcription factor of the
Forkhead family [2] is one of the key positive regulators of the cell
cycle. Both the expression and the transcriptional activity of
FoxM1 is associated with the proliferative state of cells [1]. It is
expressed in all embryonic tissues and in proliferating cells of
epithelial and mesenchymal origin [3,4]. FoxM1 plays a role in the
development of the nervous system [5] and it is required for
hepatoblast differentiation toward biliary epithelial cell lineages [6]
and for embryonic development of the pulmonary vasculature [7].
FoxM1 expression is also induced during lung and liver tissue
regeneration and repair. The transcriptional activity of FoxM1
depends on oncogenic Ras-MAPK and Sonic Hedgehog pathways
[8,9]. FoxM1 transcriptionally upregulates target genes involved in
cell cycle progression and it is critical for G1/S and G2/M
transition, and also for the execution of the mitotic program
because FoxM1-depleted cells fail to advance beyond the prophase
stage of mitosis [10].
While FoxM1 is one of the most overexpressed genes in human
solid tumors (reviewed in [11,12]), its expression is turned off in
terminally differentiated, non-dividing cells [1]. FoxM1 is
overexpressed in hepatocellular carcinomas [13], pancreatic
carcinomas [14], breast cancers [15,16], non-small cell lung
carcinomas [17], anaplastic astrocytomas and glioblastomas [18],
basal cell carcinomas [9] and intrahepatic cholangiocarcinomas
[19]. Since the function of FoxM1 is inhibited by several tumor
suppressors, such as p19-ARF, pRb, p16 and p53 and activated by
multiple oncogenic signaling pathways, FoxM1 may be classified
as a proto-oncogene. Inhibition of FoxM1 expression by small
interfering RNAs [20,21] or by a peptide containing amino acids
24–46 of p19
ARF [22,23] reduced anchorage-independent cell
growth in vitro and delayed liver tumor growth in mice. Similarly,
suppression of FoxM1 in pancreatic cancer cells by RNA
interference led to the inhibition of their metastatic potential
[24]. These studies have demonstrated that FoxM1 is essential for
cancer cell viability and its inhibition may hinder the development
of cancer, suggesting that targeting FoxM1 by small molecules
could represent a new strategy for developing novel anticancer
drugs [25,26,27,28].
Previously, using a cell-based screening system developed by our
laboratory, we identified a thiopeptide, Siomycin A (NSC-285116)
as a potent inhibitor of FoxM1 [25]. In addition, we showed that
Siomycin A and another similar thiazole antibiotic, thiostrepton,
which has already been approved by the FDA for animal use,
inhibit FoxM1 and induce apoptosis in melanoma cells [26,29].
Here, we demonstrated that thiazole antibiotics, Siomycin A and
thiostrepton inhibit FoxM1 transcriptional activity and expression.
We also found direct correlation between the suppression of
FoxM1 expression and induction of apoptosis by the thiopeptides
in different human cancer cell lines. Furthermore, we established
that FoxM1 could protect against cell death induced by the
thiazole antibiotics, suggesting that these drugs may partially exert
their anticancer activity via the suppression of FoxM1.
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Recently, we obtained evidence that another thiazole antibiotic,
thiostrepton, which structurally differs from Siomycin A by only 2
residues (Fig. 1A) possesses anti-cancer [30] and anti-FoxM1
properties [29] similar to Siomycin A. To evaluate the effects of
thiostrepton on FoxM1 transcriptional activity and also to study
how the thiazole antibiotics affect the transcriptional activity of
other members of the Forkhead family, we developed the C3-
Luc2.3-FoxO1 cell line. C3-Luc2.3-FoxO1 cells are a derivative of
U2OS osteosarcoma cells with a doxycycline-inducible FoxM1-
GFP fusion protein [25], a tamoxifen-inducible constitutively
active FoxO1(AAA)-ER fusion protein and a FoxM1/FoxO1-
dependent firefly luciferase. In this system, we were able to
selectively induce either FoxM1 transcriptional activity by the
addition of doxycycline or FoxO1 transcriptional activity by the
addition of tamoxifen. First, to test how thiostrepton affects
FoxM1 transcriptional activity compared to Siomycin A, cells were
treated with a combination of doxycycline and the thiazole
antibiotics and 16 hours later the luciferase activity was measured.
We found that the repression of FoxM1 transcriptional activity by
thiostrepton is comparable to that of Siomycin A (Fig. 1B),
indicating that both thiazole antibiotics inhibit FoxM1 transcrip-
tional activity. Next, to determine whether the thiazole antibiotics
inhibit the transcriptional activity of other Forkhead family
members such as FoxO1 [31], we treated the C3-Luc2.3-FoxO1
cell line with a combination of tamoxifen and the thiopeptides. We
found that addition of tamoxifen led to the induction of FoxO1-
dependent luciferase activity, but the treatment with the thiazole
antibiotics did not reduce this value (Fig. 1B). Since all members of
the Forkhead family share a conserved Forkhead/winged-helix
DNA-binding domain that is responsible for binding to consensus
sites, our data suggest that the thiopeptides do not target this
domain and they may negatively regulate only FoxM1, but not
other Forkhead family members.
In our previous reports we found unexpectedly that Siomycin A
not only downregulated FoxM1 transcriptional activity, but it also
reduced the mRNA and protein levels of FoxM1 [25,29]. In this
study, we demonstrated that thiostrepton also downregulates
FoxM1 protein levels to a similar extent to Siomycin A (Fig. 1C).
In addition, we found that the thiazole antibiotics did not decrease
the protein levels of other members of the Forkhead family such as
FoxA1, FoxO1 and FoxO3a (Fig. 1C), further supporting the idea
that thiazole antibiotic Siomycin A and thiostrepton are specific
inhibitors of FoxM1. To further explore the potential specificity of
the antibiotics for FoxM1-dependent transcription, we tested how
Siomycin A and thiostrepton affect the transcriptional activity of
other transcription factors such as p53, Tcf/Lef and GLI. To this
end, the HCT116-p53RE-Luc cell line (with wild-type p53 and
multiple p53 response elements upstream of the luciferase gene),
SW480 colon cancer cell line (transiently transfected with the Tcf/
Lef-dependent TOPFlash construct [32]; a gift from Dr. Randall
Moon) and A549 lung cancer cells (transiently transfected with the
GLI-dependent GLIBS-Luc reporter construct and the GLI
expression plasmid; gifts from Dr. David Robbins) were treated
with Siomycin A or thiostrepton and the luciferase activity was
measured 16 hours after treatment. We found that treatment with
the antibiotics did not reduce p53, Tcf/Lef or GLI- dependent
transcription (Fig. 1D–F). However, our further experiments
showed that the thiazole antibiotics also affect NF-kB activity,
but not the activity of other studied transcription factors (data not
shown).
To evaluate the anticancer potential of the thiazole antibiotics
we analyzed their effects on human cancer cell lines of different
origin that had elevated expression level of FoxM1. First, we
investigated whether the extrinsic or intrinsic apoptotic pathway is
involved in the thiopeptide-induced apoptosis. We treated caspase-
8 deficient and reconstituted NB7 neuroblastoma cell lines with
the antibiotics for 24 hrs (Fig. 2A). We found that caspase-8
deficient NB7 cells that cannot undergo extrinsic apoptosis were
almost as sensitive to the thiopeptides as reconstituted NB7 cells
with active caspase-8, suggesting that the thiopeptide-induced
apoptosis mainly involves the intrinsic apoptotic pathway.
To quantitatively assess the degree of sensitivity of different
human cancer cell lines to the thiazole antibiotics Siomycin A and
thiostrepton we performed growth inhibition assays on various
leukemia (CEM, HL60, U937) and liver (Hep-3B, Huh7, SK-Hep)
cancer cells. These cancer cell lines were treated with different
concentrations of the antibiotics for 48 hrs and the extent of
growth inhibition was determined by counting the number of live
cells (Fig. 2B). All of the cell lines displayed IC50s in the low
micromolar range, suggesting that these human cancer cells are
fairly sensitive to the thiopeptides. In addition, we evaluated the
apoptotic response to Siomycin A and thiostrepton in these human
cancer cells by immunoblotting for cleaved caspase-3. We found
that both Siomycin A and thiostrepton repress FoxM1 protein
expression, and induce apoptosis in these leukemia and liver
cancer cells (Fig. 2C, D). These data further support our
conclusion that thiazole antibiotics not only antagonize the
transactivation ability of FoxM1, but they also inhibit its
expression because of the FoxM1 positive feedback loop [33].
Furthermore, we observed direct correlation between FoxM1
suppression and caspase-3 cleavage (hallmark of apoptosis) after
treatment with these compounds. The close link between FoxM1
repression and induction of apoptosis suggests that the thiopep-
tides may exert their proapoptotic activity at least partially through
the inhibition of FoxM1 in human cancer cells.
To investigate the potential role of FoxM1 in the thiopeptide-
mediated apoptosis, we treated U2OS osteosarcoma cells with
10 mM of Siomycin A and harvested the cells at different time
points (Fig. 3A). We found considerable decrease in FoxM1
protein expression as early as 18 hr, which was correlated with the
appearance of robust cleaved caspase-3 bands. We also observed
correlation between stronger downregulation of FoxM1 and more
intense apoptosis after 24 hr treatment with thiostrepton in the
presence of the well-known translational inhibitor cyclohexamide
(Chx) compared to individual treatment with the drugs, again
indicating that suppression of FoxM1 may be required for the
thiopeptide-induced apoptosis (Fig. 3B). To further explore the
role of FoxM1 in the thiopeptide-mediated apoptosis we utilized
the C3 cell line [25]. FoxM1 expression was induced with the
addition of doxycycline and the following day the cells were
treated with thiostrepton and cyclohexamide for 24 hours
(Fig. 3C). We observed that the expression of endogenous FoxM1
decreased in a time-dependent manner after treatment, while the
levels of exogenous FoxM1 were not affected (Fig. 3C). We also
found that overexpression of FoxM1 protected against cell death
induced by thiostrepton as detected by immunoblotting for cleaved
caspase-3 (Fig. 3C). These data support the notion that
downregulation of FoxM1 may contribute to the thiopeptide-
induced apoptosis. Similarly, we found that C3 cells overexpress-
ing FoxM1 were resistant to the treatment with Siomycin A as
analyzed by immunoblotting for cleaved caspase-3 (Fig. 3D).
Additional experiments revealed that overexpression of FoxM1
also protects against Siomycin A-induced apoptosis in the presence
of cyclohexamide (Fig. 3E). Taken together, all these data suggest
that downregulation of FoxM1 by Siomycin A and thiostrepton
may be required for the thiopeptide-induced apoptosis.
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Previously, we reported that thiazole antibiotics Siomycin A
[25] and thiostrepton [29] inhibit FoxM1 and induce apoptosis in
human cancer cells. In this study, we demonstrated that the
thiazole antibiotics inhibit FoxM1 transcriptional activity, they
also downregulate FoxM1 expression and induce cell death in
neuroblastoma, leukemia and liver cancer cells. It is known that
the thiazole antibiotics carry out their antibacterial activity by
inhibiting bacterial translation via interaction with the 23S
ribosomal RNA, but they do not block eukaryotic protein synthesis
[34]. The precise mechanism of inhibition of FoxM1 transcrip-
tional activity remains to be elucidated, but it is not related to their
ability to inhibit protein synthesis. Interestingly, we also found that
thiazole antibiotics suppress not only the transcriptional activity,
but also the expression of FoxM1 (Fig. 1, 2), suggesting that
FoxM1 may positively regulate its own transcription [33].
Here, we found that thiazole antibiotic-induced apoptosis in
cancer cells of different origin was correlated with the downreg-
ulation of FoxM1 (Fig. 2, 3). The thiopeptides inhibited cell
growth with similar IC50 and induced cell death with comparable
concentrations in such diverse cell types as neuroblastoma,
leukemia and hepatoma (Fig. 2). Since we already reported that
Siomycin A and thiostrepton target FoxM1, inhibit cell growth
and induce apoptosis in melanoma cells [29], these data further
confirm that thiazole antibiotics may affect a wide variety of
human cancer cells. In addition, we showed that overexpression of
FoxM1 could protect cancer cells against thiopeptide-mediated
apoptosis (Fig. 3C, D, E). Since thiazole antibiotics suppress the
expression and the activity of FoxM1 and at the same time FoxM1
overexpression protects cancer cells from Siomycin A and
thiostrepton toxicity, FoxM1 may be a valid target of thiazole
antibiotic-induced apoptosis. Recently, Kwok et. al. showed that
thiostrepton represses FoxM1 expression and induces apoptosis in
breast cancer cells [35]. These data further support our present
results and the findings from our previous publications that
thiazole antibiotics, Siomycin A [25], and thiostrepton [29] induce
apoptosis and suppress FoxM1 expression in human cancer cells.
However, this group did not link suppression of FoxM1 expression
to inhibition of its transcriptional activity by thiostrepton [35]. In
addition, they claim that only constitutively active, but not
wildtype FoxM1, may inhibit thiostrepton antiproliferative activity
[35]. Further experiments are needed to resolve these differences.
In summary, we demonstrated that thiazole antibiotics
Siomycin A and thiostrepton are potent inhibitors of FoxM1
transcriptional activity and expression. In addition, they induce
programmed cell death in human cancer cells of diverse origin.
The degree of apoptosis induced by the thiopeptides correlates
with the suppression of FoxM1, while overexpression of wild type
FoxM1 partially protected cancer cells from thiopeptide-induced
apoptosis. These data suggest that inhibition of FoxM1 by
Siomycin A and thiostrepton to some extent is responsible for
the cell death induced by the thiazole antibiotics. The experiments
described in this manuscript support our earlier reports
[25,26,27,29] that FoxM1 is an appropriate target for anticancer
drugs and that thiazole antibiotics could represent promising
alternatives to presently used anticancer treatments.
Materials and Methods
Cell lines, media and chemical compounds
U2OS osteosarcoma cells; C3 cells [22], a U2OS clone C3 cell
line with doxycycline-inducible FoxM1-GFP fusion protein; U2OS
derived C3-Luc2.3-FoxO1 osteosarcoma, stably expressing the
doxycycline-inducible FoxM1-GFP [25], the tamoxifen-inducible
FoxO1(AAA)-ER fusion protein and firefly luciferase under the
control of multiple FoxM1/FoxO1 responsive elements; HCT116-
p53RE-Luc colon, stably expressing firefly luciferase under the
controlof a promoter with multiple p53response elements (p53RE);
A549 lung and Huh7, Hep3B and SK-Hep liver cancer cell lines
were grown in DMEM medium (Invitrogen). SW480 colon,
caspase-8 deficient and reconstituted NB7 neuroblastoma (generous
gifts from Dr. Jill M. Lahti, St. Jude Children’s Research Hospital,
Memphis), CEM, HL60 and U937 leukemia cancer cell lines were
grown in RPMI 1640 medium (Invitrogen). In all cases the media
were supplemented with 10% fetal bovine serum (Atlanta
Biologicals) and 1% penicillin-streptomycin (GIBCO) and the cell
lineswerekept at37uCin5%CO 2.ThiazoleantibioticsSiomycin A
(NCI) and thiostrepton (Sigma) were dissolved in DMSO
(dimethylsulfoxide), tamoxifen (Sigma) in ethanol, doxycycline
(Clontech) in PBS and cyclohexamide (Sigma) in DMSO.
Constructs and transfections
The Super8xTOPFlash and the control Super8xFOPFlash
reporter plasmids were generous gifts from Dr. Randall T Moon
(University of Washington, Seattle, WA). The SRaGLI1 expres-
sion plasmid and the GLI-BS-Luc, miniTK reporter constructs
were kind gifts from Dr. David J. Robbins (Dartmouth Medical
School, Hanover, NH). Transient transfections were carried out
using Lipofectamine 2000 (Invitrogen) according to the instruc-
tions of the manufacturer.
Immunoblot analysis
Cancer cells of different origin treated as indicated were
harvested and lysed by using IP buffer (20 mM HEPES, 1%
Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
100 mM NaF, 10 mM Na4P2O7, 1 mM sodium othrovanadate,
0.2 mM PMSF supplemented with protease inhibitor tablet
(Roche Applied Sciences)). Protein concentration was determined
by the Bio-Rad Protein Assay reagent (BIO-RAD). Isolated
Figure 1. Thiazole antibiotics inhibit FoxM1-dependent transcription and FoxM1 expression. (A) The chemical structure of the thiazole
antibiotic, thiostrepton that differs from Siomycin A by only two residues (Thiostrepton-R1-R2: Isoleucine-alanine; Siomycin- R1-R2: valine-
dehydroalanine). (B) Luciferase assays after treatment of the C3-Luc2.3-FoxO1 cell line with the combination of either 1 mg/mL doxycycline (Doxy) or
300 nM tamoxifen (Tam) and 3 mM of Siomycin A (Sio) or thiostrepton (Tio), respectively revealed that thiostrepton is also a negative regulator of
FoxM1 transcriptional activity and thiazole antibiotics inhibit FoxM1 transcriptional activity among the Forkhead family members. (C) Thiazole
antibiotics downregulated FoxM1 protein levels, but not FoxA1, FoxO1 and FoxO3a levels as detected by immunoblotting. (D) The HCT116-p53RE-
Luc cell line, which stably expressing firefly luciferase under the control of multiple p53 response elements treated with the indicated concentration
of Siomycin A or thiostrepton. After overnight treatment the luciferase activity was measured. (E) SW480 colon cancer cell line was transiently
transfected with the Tcf/Lef-dependent TOPFlash and the control FOPFlash constructs. Twenty-four hrs following transfection the cells were treated
with 3 mM of Siomycin A or thiostrepton. The next day the luciferase activity was measured. (F) A549 lung cancer cells were transiently transfected
with the GLI-dependent GLIBS-Luc, the control miniTK reporter constructs and the GLI expression plasmid. Cells were treated with the indicated
concentration of the thiopeptides 24 hrs after transfection and the luciferase activity was measured the following day. Bars in B, D–F are
representative mean values of triplicate experiments+/2SD.
doi:10.1371/journal.pone.0005592.g001
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transferred to PVDF membrane (Millipore). Immunoblotting
was carried out as described in 34, 35 with antibodies specific
for FoxM1 (a gift from Dr. Costa’s lab), FoxA1 (a gift from Dr.
Costa’s lab), FoxO1 (Cell Signaling), FoxO3a (Upstate), Cleaved
caspase-3 (Cell signaling) and b-actin (Sigma).
Luciferase assays
C3-Luc2.3-FoxO1 cells were grown on 6-well plates and treated
overnight with the combination of either 1 mg/mL doxycycline or
300 nM tamoxifen and 3 mM of Siomycin A or thiostrepton. Also,
the HCT116-p53RE-Luc cell line was grown on 6-well plates and
treated with 3 mM of Siomycin A or thiostrepton for 16 hrs.
Furthermore, SW480 colon cancer cell line grown on 6-well plates
was transiently transfected with the TOPFlash and the FOPFlash
constructs. Twenty-four hrs following transfection the cells were
treated with 3 mM of Siomycin A or thiostrepton. The next day
the firefly luciferase activity was measured using the Luciferase
Assay System (Promega). Protein concentration measured by the
Bio-Rad Protein Assay reagent (BIO-RAD) was used for
Figure 2. Evaluation of the effects of the thiopeptides on a panel of human cancer cell lines. (A) Treatment of caspase-8 deficient and
reconstituted NB7 neuroblastoma cell lines with the thiazole antibiotics revealed that thiopeptide-induced apoptosis mainly involves the intrinsic
apoptotic pathway. (B) Leukemia cancercell lines CEM [IC50/mM: Sio-0.73 (0.08); Thio-1.47 (0.1)],HL60 [IC50/mM: Sio-0.68 (0.06); Thio-1.78 (0.4)], and U937
[IC50/mM: Sio-0.53 (0.1); Thio-0.73 (0.3)], and liver cancercell lines Hep-3B [IC50/mM: Sio-3.6 (1.3); Thio-2.3 (0.8)],Huh7 [IC50/mM: Sio-2.3 (0.5); Thio-1.8 (0.2)],
and SK-Hep [IC50/mM: Sio-3.7 (0.4); Thio-6.0 (1.4)], showed sensitivity in low micromolar range to the thiazole antibiotics as determined by growth
inhibition assays. (C–D) Siomycin A and thiostrepton inhibit FoxM1 expression and induce potent apoptosis in leukemia and liver cancer cells.
doi:10.1371/journal.pone.0005592.g002
Figure 3. Overexpression of FoxM1 partially protects cancer cell lines from thiazole antibiotic-induced apoptosis. (A) Immunoblot
analysis after treatment with Siomycin A revealed close correlation between downregulation of FoxM1 and induction of apoptosis. (B) Following
treatment with thiostrepton, thiopeptide-induced apoptosis and inhibition of FoxM1 protein expression are more prominent in the presence of
cyclohexamide (Chx) as depicted by immunoblotting for FoxM1 and cleaved caspase-3. (C) The expression of endogenous FoxM1 decreased in a
time-dependent fashion in the presence of thiostrepton and Chx, while the levels of exogenous FoxM1 were not affected. Overexpression of FoxM1
protected against cell death induced by thiostrepton as detected by immunoblotting for cleaved caspase-3. (D) FoxM1 overexpressing cells were
resistant to the treatment with increasing amount of Siomycin A as analyzed by immunoblotting for cleaved caspase-3. (E) Immunoblot analysis
revealed that overexpression of FoxM1 also protected against Siomycin A-induced apoptosis in the presence of Chx.
doi:10.1371/journal.pone.0005592.g003
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5592normalization. A549 lung cancer cells grown on 6-well plates were
transiently cotransfected with either the GLI-dependent GLIBS-
Luc or the control miniTK reporter constructs, the GLI
expression plasmid and pRL-null (Promega) that expresses renilla
luciferase. Cells were treated with 3 mM of Siomycin A or
thiostrepton 24 hrs after transfection and the luciferase activity
was measured with the Dual-Luciferase Reporter Assay System
(Promega) according to the manufacturer’s instructions the
following day.
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